Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,208 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Powder Clear all

Conditions: Infant Development
Interventions: BBN, Brand; Other
Lead sponsor: Building Block Nutritionals, LLC; Industry
Eligibility: 1 Day to 14 Days
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Birmingham, Alabama • Dothan, Alabama • Norwich, Connecticut + 3 more

Conditions: Small Intestinal Bacterial Overgrowth
Interventions: Novel Supplement Based Therapy; Dietary Supplement
Lead sponsor: Atrium Innovations; Industry
Eligibility: 19 Years to 84 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Oxford, Ohio

Conditions: Tuberous Sclerosis Complex, Epilepsy
Interventions: TAVT-18 (sirolimus); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day to 6 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Leukemia
Interventions: Dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 1 Day to 18 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 11 more

Conditions: Low-grade Glioma, Advanced Solid Tumor
Interventions: Tovorafenib; Drug
Lead sponsor: Day One Biopharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 25 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 11 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 59
States / cities: *See Various Dept.'s*, Arizona • Chandler, Arizona • Fresno, California + 48 more

Conditions: Glioblastoma Multiforme
Interventions: arginine in powder form, Silica and cellulose placebo powder; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Intestinal Multi-drug Resistant Organism Colonization
Interventions: Microbiome Therapeutic, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Hypoglycemia, Diabetes Mellitus
Interventions: Nasal Glucagon; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 3
States / cities: Tallahassee, Florida • Baltimore, Maryland • Waltham, Massachusetts

Conditions: PGM3
Interventions: N-Acetylglucosamine (GlcNAc), Uridine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes, Ketone Body Metabolism, Ketones, Metabolism
Interventions: Ketone Ester Acute, Placebo Acute; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Solid Tumours
Interventions: Pazopanib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 24
States / cities: Long Beach, California • Madera, California • Orange, California + 21 more

Conditions: Asthma
Interventions: Fluticasone propionate 100mcg, Placebo, Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 34
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 31 more

Conditions: Healthy Volunteers
Interventions: ALZT-OP1a, ALZT-OP1b, Dry Powder Inhaler; Drug · Device
Lead sponsor: AZTherapies, Inc.; Industry
Eligibility: 55 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Obesity
Interventions: Blueberry Smoothie, Sham Smoothie; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: COPD
Interventions: Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer); Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Cancer-related Fatigue
Interventions: Guarana herb, Usual Care; Dietary Supplement · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Common Cold
Interventions: Bifidobacterium lactis Bl-04, Placebo, Rhinovirus; Dietary Supplement · Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 60 Years
Enrollment: 789 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Systemic Juvenile Idiopathic Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Type 2 Diabetes Mellitus
Interventions: LY3209590, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 31
States / cities: Sheffield, Alabama • Huntington Park, California • Los Angeles, California + 26 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Albuterol sulfate (ABS); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 40
States / cities: Andalusia, Alabama • Anniston, Alabama • Mobile, Alabama + 34 more

Conditions: Vaccine Adverse Reaction, Post Acute Covid-19 Vaccination Syndrome
Interventions: Combined metabolic modulator, Rice Protein Powder with Vitamin C; Combination Product · Dietary Supplement
Lead sponsor: Independent Medical Alliance; Other
Eligibility: 16 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232, Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ileal Pouch
Interventions: EXE-346, Placebo; Biological · Other
Lead sponsor: Exegi Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 5 more

Search by objective public record fields.

Growth and Safety Study of an Infant Formula for Healthy Term Infants

Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth

Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NVA237 BID Versus Placebo Twelve-week Efficacy Study

Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme

Further MT for Antibiotic-Resistant Bacterial Colonization

Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation

Effects of Ketone Ester Consumption on Exercise Tolerance and Cardiac Function

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers

The Health Effects of a Blueberry Enriched Diet on Obese Children

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

Effect of High-Dose Guarana And Cancer-Related Fatigue

Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)